Prospect of Vasactive Intestinal Peptide Therapy for COPDPAH and Asthma
- 저자
- 성*길
- 게재저널
- Respiratory Research (http://respiratory-research.com/content/12/1/45)
- 키워드
- 개요
-
There is mounting evidence that pulmonary arterial hypertension (PAH), asthma and chronic obstructive pulmonary
disease (COPD) share important pathological features, including inflammation, smooth muscle contraction and
remodeling. No existing drug provides the combined potential advantages of reducing vascular- and bronchialconstriction,
and anti-inflammation. Vasoactive intestinal peptide (VIP) is widely expressed throughout the
cardiopulmonary system and exerts a variety of biological actions, including potent vascular and airway dilatory
actions, potent anti-inflammatory actions, improving blood circulation to the heart and lung, and modulation of
airway secretions. VIP has emerged as a promising drug candidate for the treatment of cardiopulmonary disorders
such as PAH, asthma, and COPD. Clinical application of VIP has been limited in the past for a number of reasons,
including its short plasma half-life and difficulty in administration routes. The development of long-acting VIP
analogues, in combination with appropriate drug delivery systems, may provide clinically useful agents for the
treatment of PAH, asthma, and COPD. This article reviews the physiological significance of VIP in cardiopulmonary
system and the therapeutic potential of VIP-based agents in the treatment of pulmonary diseases.
- 첨부파일
-
이미지변환중입니다.
